Adenoviral Conjunctivitis

Interim results from a phase 2 study showed that Okogen’s topical OKG-0301 provided a safe and effective dose-dependent antiviral response in patients with acute adenoviral conjunctivitis, according to a poster presented at ARVO.

ORLANDO, Fla. – A single in-office dose of 5% povidone-iodine in patients who tested positive for adenoviral conjunctivitis resulted in an improvement in signs and symptoms and a decrease in viral titers.